Ivabradine induces RAD51 degradation, potentiating PARP inhibitor efficacy in non-germline BRCA pathogenic variant triple-negative breast cancer

Abstract Background Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targetable proteins for treatment. PARP inhibitors (PARPi) are effective in BRCA-mutated cancers but have limited utility in non-germline BRCA-mutated (non-gBRCAm) TNBC. We hypothesized that inducing BRCAness b...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ho Tsoi, George Man Hong Leung, Ellen Pui Sum Man, Chan Ping You, Koei Ho Lam Cheung, Kelvin Yuen Kwong Chan, Chun Gong, Michael Shing Yan Huen, Ui Soon Khoo
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2025-08-01
Edice:	Journal of Translational Medicine
Témata:	Breast cancer BRCAness Ivabradine Olaparib Synthetic lethality Targeted therapy
On-line přístup:	https://doi.org/10.1186/s12967-025-06902-8
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!